ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia

    NEXT STORY
    Eurobio Scientific: CNR validation of two COVID-19 serology tests
    PREV STORY
    iTeos Therapeutics Strengthens Leadership Team  
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Paratek Mourns Passing of Co-founder Dr. Stuart Levy

    author_avatar
    NASDAQ Market News

    PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline

    author_avatar
    NASDAQ Market News

    New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

    - Safety Profile of Combination Therapies Consistent with Single Agent IDHm Inhibitors and Azacitidine ...

    author_avatar
    NASDAQ Market News